Decision models for assessing the cost effectiveness of drug-eluting stents

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 6, 2005, Pages 965-974

  Kong, David F ^a   Eisenstein, Eric L ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Angioplasty; Computer simulation; Coronary disease; Cost benefit analysis; Cost effectiveness; Decision model; Drug eluting stent; Health insurance reimbursement; Hospital costs; Percutaneous coronary; Transluminal

Indexed keywords

CLINICAL PRACTICE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG ELUTING STENT; HIGH RISK PATIENT; HOSPITAL PLANNING; HUMAN; NONBIOLOGICAL MODEL; PERCUTANEOUS CORONARY INTERVENTION; QUALITY ADJUSTED LIFE YEAR; REVIEW; SOCIETY; TECHNOLOGY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG DELIVERY SYSTEMS; GROWTH INHIBITORS; HUMANS; STENTS;

EID: 21744457078     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.6.965     Document Type: Review

References (29)

1. ARNESEN T, NORD E: The value of DALY life: problems with ethics and validity of disability adjusted life years. Br. Med. J. (1999) 319:1423-1425.
2. BITTL JA: Medical progress: advances in coronary angioplasty. N. Engl J. Med. (1996) 335:1290-1302.
3. HODGSON JM, BOTTNER RK, KLEIN LW et al.: Drug-eluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues. Catheter Cardiovasc. Interv. (2004) 62:1-17.
4. HOFFMANN R, MINTZ GS, DUSSAILLANT GR et al.: Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation (1996) 94:1247-1254.
5. SERRUYS PW, UNGER F, SOUSA JE et al.: Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N. Engl. J. Med. (2001) 344:1117-1124.
6. GREENBERG D, BAKHAI A, COHEN DJ: Can we afford to eliminate restenosis? Can we afford not to? J. Am. Coll. Cardiol. (2004) 43:513-518.
7. BABAPULLE MN, JOSEPH L, BELISLE P, BROPHY JM, EISENBERG MJ: A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting scents. Lancet (2004) 364:583-591.
8. LIISTRO F, STANKOVIC G, DI MARIO C et al.: First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation (2002) 105:1883-1886.
9. GREENBERG D, COHEN DJ: Examining the economic impact of restenosis: implications for the cost-effectiveness of an antiproliferative stent. Z. Kardiol. (2002) 91(Suppl. 3):137-143.
10. KONG DF, EISENSTEIN EL, SKETCH MH et al.: Economic impact of drug-eluting stents on hospital systems: a disease-state model. Am. Heart J. (2004) 147:449-456.
11. COHEN DJ, SUKIN CA: Cost-effectiveness of coronary interventions. Heart (1997) 78(Suppl. 2):7-10.
12. COHEN DJ: Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluation of the cost-effectiveness of coronary stenting: a societal perspective. Am. Heart J. (1999) 137:S133-S137.
13. MARK DB, HLATKY MA: Medical economics and the assessment of value in cardiovascular medicine: Part II. Circulation (2002) 106:626-630.
14. MARK DB, HLATKY MA: Medical economics and the assessment of value in cardiovascular medicine: Part I. Circulation (2002) 106:516-520.
15. CUTLIP DE, CHAUHAN MS, BAIM DS et al.: Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J. Am. Coll. Cardiol. (2002) 40:2082-2089.
16. RINFRET S, GRINES CL, COSGROVE RS et al.: Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One-year results from the Stent-PAMI trial. J. Am. Coll. Cardiol. (2001) 38:1614-1621.
17. WEAVER WD, REISMAN MA, GRIFFIN JJ et al.: Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial. Lancet (2000) 355:2199-2203.
18. EISENSTEIN EL, MARK DB: Cost effectiveness of new diagnostic tools and therapies for acute coronary syndromes. In: Acute Coronary Syndromes. EJ Topol (Ed.), Marcel Dekker, New York, NY, USA (2004):723-745.
19. BROPHY J, ERICKSON L: An economic analysis of drug eluting coronary stents: a Québec perspective. Montreal, Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS). (2004) 04.
20. O'NEILL WW, LEON MB: Drug-eluting stents - costs versus clinical benefit. Circulation (2003) 107:3008-3011.
21. EISENSTEIN EL, PETERSON ED, JOLLIS JG et al.: Evaluating the potential 'economic attractiveness' of new therapies in patients with non-ST elevation acute coronary syndrome. Pharmacoeconomics (2000) 17:263-272.
22. GOLDMAN L, WEINSTEIN MC, GOLDMAN PA, WILLIAMS LW: cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA (1991) 265:1145-1151.
23. KAHN JG, HAILE B, KATES J, CHANG S: Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid. Am. J. Public Health (2001) 91:1464-1473.
24. PHILLIPS KA, SHLIPAK MG, COXSON P et al.: Health and economic benefits of increased beta-blocker use following myocardial infarction. JAMA (2000) 284:2748-2754.
25. BAUTERS C, HUBERT E, PRAT A et al.: Predictors of restenosis after coronary stent implantation. J. Am. Coll. Cardiol. (1998) 31:1291-1298.
26. KASTRATI A, SCHULEN H, HAUSLEITER J et al.: Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. Circulation (1997) 96:462-467.
27. KITAZUME H, ICHIRO K, IWAMA T, AGEISHI Y: Repeat coronary angioplasty as the treatment of choice for restenosis. Am. Heart J. (1996) 132:711-715.
28. MORICE MC, SERRUYS PW, SOUSA JE et al.: Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. (2002) 346:1773-1780.
29. GRIFFITHS H, BAKHAI A, WEST D et al.: Feasibility and cost of treatment with drug eluting stents of surgical candidates with multi-vessel coronary disease. Eur. J. Cardiothorac. Surg. (2004) 26:528-534.